Diabetes Brands

Prescription diabetes medication for treating type 2 diabetes by increasing insulin secretion, manufactured and marketed by Merck & Co.

Sanofi's long-acting insulin glargine for type 1 and type 2 diabetes, FDA approved April 2000, that reached peak global sales of $6.4 billion in 2015 before biosimilar competition from Basaglar, Semglee, and Rezvoglar significantly eroded its market share and revenues.

Pharmaceutical brand of tirzepatide injection for type 2 diabetes treatment, owned by Eli Lilly and Company.

Danish multinational pharmaceutical company and the world's leading manufacturer of diabetes and obesity medications, including Ozempic, Wegovy, and Victoza, listed on the Copenhagen Stock Exchange and NYSE.

Prescription diabetes medication brand owned by Novo Nordisk, containing semaglutide as the active ingredient.